Tower Research Capital (TRC)’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.3K | Buy |
+1,718
| New | +$2.83K | ﹤0.01% | 4501 |
|
|
2025
Q4 | – | Sell |
-3,933
| Closed | -$10.1K | – | 5178 |
|
|
2025
Q3 | $10.1K | Buy |
3,933
+2,563
| +187% | +$8.08K | ﹤0.01% | 4001 |
|
|
2025
Q2 | $2.48K | Buy |
1,370
+1,218
| +801% | +$2.02K | ﹤0.01% | 4647 |
|
|
2025
Q1 | $309 | Buy |
152
+136
| +850% | +$508 | ﹤0.01% | 4944 |
|
|
2024
Q4 | $97 | Sell |
16
-671
| -98% | -$5.61K | ﹤0.01% | 5471 |
|
|
2024
Q3 | $6.71K | Sell |
687
-68
| -9% | -$914 | ﹤0.01% | 4113 |
|
|
2024
Q2 | $15.5K | Buy |
755
+466
| +161% | +$15.6K | ﹤0.01% | 3904 |
|
|
2024
Q1 | $13K | Sell |
289
-576
| -67% | -$27.5K | ﹤0.01% | 3422 |
|
|
2023
Q4 | $40.8K | Buy |
865
+610
| +239% | +$33.9K | ﹤0.01% | 3263 |
|
|
2023
Q3 | $10.3K | Sell |
255
-100
| -28% | -$10.1K | ﹤0.01% | 4124 |
|
|
2023
Q2 | $37.8K | Buy |
355
+259
| +270% | +$86.2K | ﹤0.01% | 2821 |
|
|
2023
Q1 | $29K | Buy |
96
+65
| +210% | +$27.8K | ﹤0.01% | 3020 |
|
|
2022
Q4 | $11K | Sell |
31
-47
| -60% | -$11.4K | ﹤0.01% | 3792 |
|
|
2022
Q3 | $15K | Sell |
78
-86
| -52% | -$20K | ﹤0.01% | 4157 |
|
|
2022
Q2 | $35K | Sell |
164
-43
| -21% | -$9.04K | ﹤0.01% | 3206 |
|
|
2022
Q1 | $69K | Sell |
207
-86
| -29% | -$24.9K | ﹤0.01% | 2476 |
|
|
2021
Q4 | $95K | Hold |
293
| – | – | ﹤0.01% | 2254 |
|
|
2021
Q3 | $143K | Buy |
293
+242
| +475% | +$106K | ﹤0.01% | 2099 |
|
|
2021
Q2 | $23K | Sell |
51
-56
| -52% | -$30.5K | ﹤0.01% | 3751 |
|
|
2021
Q1 | $74K | Buy |
107
+101
| +1,683% | +$81.2K | ﹤0.01% | 2810 |
|
|
2020
Q4 | $4K | Sell |
6
-105
| -95% | -$81.8K | ﹤0.01% | 4688 |
|
|
2020
Q3 | $77K | Sell |
111
-262
| -70% | -$197K | ﹤0.01% | 3328 |
|
|
2020
Q2 | $316K | Buy |
373
+366
| +5,229% | +$239K | 0.01% | 1397 |
|
|
2020
Q1 | $3K | Buy |
+7
| New | +$2.52K | ﹤0.01% | 2445 |
|
|
2019
Q4 | – | Sell |
-81
| Closed | -$9K | – | 3575 |
|
|
2019
Q3 | $9K | Buy |
81
+57
| +238% | +$8.99K | ﹤0.01% | 2981 |
|
|
2019
Q2 | $4K | Buy |
+24
| New | +$4.07K | ﹤0.01% | 3009 |
|
|
2019
Q1 | – | Sell |
-70
| Closed | -$4K | – | 3805 |
|
|
2018
Q4 | $4K | Buy |
70
+50
| +250% | +$4.22K | ﹤0.01% | 3001 |
|
|
2018
Q3 | $2K | Buy |
+20
| New | +$2.97K | ﹤0.01% | 3409 |
|
|
2018
Q2 | – | Sell |
-6
| Closed | -$1K | – | 3656 |
|
|
2018
Q1 | $1K | Buy |
+6
| New | +$1K | ﹤0.01% | 3048 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
Tower Research Capital (TRC)'s BTAI Position: Q1 2026 in Review
Tower Research Capital (TRC) opened a new position in BioXcel Therapeutics (BTAI) in Q1 2026: 1,718 shares worth $2.3K. The stake represents ﹤0.01% of the portfolio and ranks #4501 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BTAI as recently as Q3 2025.
Tower Research Capital (TRC) first reported a position in BTAI in Q1 2018 and has held it in 29 quarters since. The position peaked at $316K in Q2 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- Tower Research Capital (TRC) held 1,718 shares of BioXcel Therapeutics worth $2.3K as of Q1 2026.
- BioXcel Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
- BioXcel Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4501 holding.
- Tower Research Capital (TRC) first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 29 quarters since.
- Tower Research Capital (TRC)'s BioXcel Therapeutics position peaked at $316K in Q2 2020.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.